Peripheral

TAVI: la estrategia minimalista es favorable en el EPOC severo

Are Elevated Lipoprotein (a) Levels Associated with Increased Adverse Events After Peripheral Endovascular Treatment?

Peripheral arterial disease is a manifestation of systemic atherosclerotic disease with increasing prevalence. Moreover, this disease is associated with a high risk of mortality and cardiovascular events. Lipoprotein (a) (Lp a)—which has a proatherogenic, proinflammatory, and antifibrinolytic role—has been shown to be related to major cardiovascular events and peripheral vascular events after acute coronary syndromes<a href="https://solaci.org/en/2022/07/29/are-elevated-lipoprotein-a-levels-associated-with-increased-adverse-events-after-peripheral-endovascular-treatment/" title="Read more" >...</a>

SOLACI Peripheral Registry Surpassed the 500-Patient Mark

We are glad to announce that the Latin American SOLACI Peripheral Registry keeps growing and has enrolled over 500&nbsp;patients. Over 9 countries and 29 Latin American sites have joined this multicenter, prospective research initiative that aims to collect data on the reality of lower limb angioplasty within our continent, in order to unify criteria, draw<a href="https://solaci.org/en/2022/04/08/solaci-peripheral-registry-surpassed-the-500-patient-mark/" title="Read more" >...</a>

The Most Read Articles of 2021 - Peripheral Vascular Disease

The Most Read Articles of 2021: Peripheral Vascular Disease

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. 01- SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization Dr. Ana Paula Mollón (Arg.)<a href="https://solaci.org/en/2021/12/17/the-most-read-articles-of-2021-peripheral-vascular-disease/" title="Read more" >...</a>

SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Daniel Zanuttini (Arg.) presents “Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection”. This is the 8th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences<a href="https://solaci.org/en/2021/08/24/solaci-peripheral-type-ib-endoleak-correction-in-patient-after-minimally-invasive-hybrid-treatment-in-type-a-aortic-disection/" title="Read more" >...</a>

SOLACI Research | Invitation to Participate in the Latin American SOLACI Peripheral Registry

After much effort, SOLACI Research is pleased to formally invite the entire community to participate in the Latin American SOLACI Peripheral Registry, our second research initiative.&nbsp; The SOLACI Peripheral Registry is a multicenter, prospective registry that aims to collect data on the reality of lower limb angioplasty in Latin America, in order to unify criteria,<a href="https://solaci.org/en/2021/07/16/solaci-research-invitation-to-participate-in-the-latin-american-solaci-peripheral-registry/" title="Read more" >...</a>

Programas de ejercicios en la enfermedad vascular periférica

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD). However, many participants randomized to exercise did not perceive changes, and sometimes even got worse.&nbsp; These findings suggest a significant discrepancy between objective and perceived change in walking ability among PAD patients.&nbsp;&nbsp; 400 patients with peripheral artery disease<a href="https://solaci.org/en/2021/07/15/discrepancy-between-angina-and-ischemia-repeats-in-peripheral-artery-disease/" title="Read more" >...</a>

SOLACI PERIPHERAL | 7th Clinical Case: Percutaneous Treatment for Nutcracker Syndrome

New SOLACI PERIPHERAL clinical case to keep learning among peers! Dr. Carlos Eduardo Díniz Couto shares a “Nutcracker” case from Belo Horizonte, Brazil. This is the 7th clinical case presented by SOLACI Peripheral on the SOLACI website. This space is intended to further promote and share experiences and opinions in order to continue improving our<a href="https://solaci.org/en/2021/07/06/solaci-peripheral-7th-clinical-case-percutaneous-treatment-for-nutcracker-syndrome/" title="Read more" >...</a>

ACC 2021 | VOYAGER PAD: utilidad del rivaroxaban luego de una angioplastia periférica

ACC 2021 | VOYAGER PAD: Usefulness of Rivaroxaban After Peripheral Angioplasty

Patients with peripheral vascular disease who undergo angioplasty in the lower limbs find benefit from treatment with rivaroxaban, according to the VOYAGER PAD study, presented at the scientific sessions of the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JACC. Patients with said disease present a higher risk of ischemic events not<a href="https://solaci.org/en/2021/05/21/acc-2021-voyager-pad-usefulness-of-rivaroxaban-after-peripheral-angioplasty/" title="Read more" >...</a>

SAFE-PAD: Dispositivos liberadores de paclitaxel en enfermedad periférica

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between all-cause mortality and paclitaxel-eluting devices in peripheral vascular disease. According to data from SAFE-PAD, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JAMA, there is no increase in mortality compared with conventional<a href="https://solaci.org/en/2021/05/19/acc-2021-safe-pad-paclitaxel-eluting-devices-in-peripheral-disease/" title="Read more" >...</a>

Top